Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.[Proc Natl Acad Sci U S A. 1988]

Di Chiara G, Imperato A

Proc Natl Acad Sci U S A. 1988 Jul; 85(14):5274-8.
Review The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?[Neurosci Biobehav Rev. 2006]

Pierce RC, Kumaresan V

Neurosci Biobehav Rev. 2006; 30(2):215-38.
Review The dopamine hypothesis of reward: past and current status.[Trends Neurosci. 1999]

Spanagel R, Weiss F

Trends Neurosci. 1999 Nov; 22(11):521-7.
On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine.[Pharmacol Biochem Behav. 1977]

Roberts DC, Corcoran ME, Fibiger HC

Pharmacol Biochem Behav. 1977 Jun; 6(6):615-20.
Review Brain mechanisms of drug reward and euphoria.[Psychiatr Med. 1985]

Wise RA, Bozarth MA

Psychiatr Med. 1985; 3(4):445-60.
Cocaine receptors on dopamine transporters are related to self-administration of cocaine.[Science. 1987]

Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ

Science. 1987 Sep 4; 237(4819):1219-23.
Subsecond dopamine release promotes cocaine seeking.[Nature. 2003]

Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM

Nature. 2003 Apr 10; 422(6932):614-8.
Neural encoding of cocaine-seeking behavior is coincident with phasic dopamine release in the accumbens core and shell.[Eur J Neurosci. 2009]

Owesson-White CA, Ariansen J, Stuber GD, Cleaveland NA, Cheer JF, Wightman RM, Carelli RM

Eur J Neurosci. 2009 Sep; 30(6):1117-27.
Review Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.[Ann N Y Acad Sci. 2001]

Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR

Ann N Y Acad Sci. 2001 Jun; 937():1-26.
Review Neurobiological substrates for the dark side of compulsivity in addiction.[Neuropharmacology. 2009]

Koob GF

Neuropharmacology. 2009; 56 Suppl 1():18-31.

Review Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.[Neuroscience. 1991]

Grace AA

Neuroscience. 1991; 41(1):1-24.
Influence of phasic and tonic dopamine release on receptor activation.[J Neurosci. 2010]

Dreyer JK, Herrik KF, Berg RW, Hounsgaard JD

J Neurosci. 2010 Oct 20; 30(42):14273-83.
Subsecond dopamine release promotes cocaine seeking.[Nature. 2003]

Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM

Nature. 2003 Apr 10; 422(6932):614-8.

Marijuana: harder than thought?[Science. 1997]

Wickelgren I

Science. 1997 Jun 27; 276(5321):1967-8.
Review Marijuana's interaction with brain reward systems: update 1991.[Pharmacol Biochem Behav. 1991]

Gardner EL, Lowinson JH

Pharmacol Biochem Behav. 1991 Nov; 40(3):571-80.
THC does not affect striatal dopamine release: microdialysis in freely moving rats.[Pharmacol Biochem Behav. 1991]

Castañeda E, Moss DE, Oddie SD, Whishaw IQ

Pharmacol Biochem Behav. 1991 Nov; 40(3):587-91.
The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study.[Brain Res. 1988]

Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL

Brain Res. 1988 Jun 7; 451(1-2):59-68.
Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis.[Psychopharmacology (Berl). 1990]

Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL

Psychopharmacology (Berl). 1990; 102(2):156-62.
Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study.[Neurosci Lett. 1991]

Chen JP, Paredes W, Lowinson JH, Gardner EL

Neurosci Lett. 1991 Aug 5; 129(1):136-80.
Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient.[Brain Res. 1993]

Chen J, Marmur R, Pulles A, Paredes W, Gardner EL

Brain Res. 1993 Sep 3; 621(1):65-70.
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.[Science. 1997]

Tanda G, Pontieri FE, Di Chiara G

Science. 1997 Jun 27; 276(5321):2048-50.
Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.[Br J Pharmacol. 1999]

Malone DT, Taylor DA

Br J Pharmacol. 1999 Sep; 128(1):21-6.
Review Addictive potential of cannabinoids: the underlying neurobiology.[Chem Phys Lipids. 2002]

Gardner EL

Chem Phys Lipids. 2002 Dec 31; 121(1-2):267-90.
Review Endocannabinoid signaling system and brain reward: emphasis on dopamine.[Pharmacol Biochem Behav. 2005]

Gardner EL

Pharmacol Biochem Behav. 2005 Jun; 81(2):263-84.
delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.[Neurosci Lett. 1997]

French ED

Neurosci Lett. 1997 May 2; 226(3):159-62.
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra.[Neuroreport. 1997]

French ED, Dillon K, Wu X

Neuroreport. 1997 Feb 10; 8(3):649-52.
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.[Eur J Pharmacol. 1998]

Gessa GL, Melis M, Muntoni AL, Diana M

Eur J Pharmacol. 1998 Jan 2; 341(1):39-44.
Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment.[Neuropharmacology. 2000]

Wu X, French ED

Neuropharmacology. 2000 Jan 28; 39(3):391-8.

Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.[Eur J Pharmacol. 1999]

Tanda G, Loddo P, Di Chiara G

Eur J Pharmacol. 1999 Jul 2; 376(1-2):23-6.
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.[Eur J Pharmacol. 1998]

Gessa GL, Melis M, Muntoni AL, Diana M

Eur J Pharmacol. 1998 Jan 2; 341(1):39-44.
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.[J Neurosci. 2004]

Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM

J Neurosci. 2004 May 5; 24(18):4393-400.

Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.[J Neurosci. 2004]

Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM

J Neurosci. 2004 May 5; 24(18):4393-400.
Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry.[Neuroscience. 1988]

Gonon FG

Neuroscience. 1988 Jan; 24(1):19-28.
Synaptic overflow of dopamine in the nucleus accumbens arises from neuronal activity in the ventral tegmental area.[J Neurosci. 2009]

Sombers LA, Beyene M, Carelli RM, Wightman RM

J Neurosci. 2009 Feb 11; 29(6):1735-42.
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.[Eur J Pharmacol. 1998]

Gessa GL, Melis M, Muntoni AL, Diana M

Eur J Pharmacol. 1998 Jan 2; 341(1):39-44.

Pretreatment with delta 1-tetrahydrocannabinol and psychoactive drugs: effects on uptake of biogenic amines and on behavior.[Eur J Pharmacol. 1979]

Hershkowitz M, Szechtman H

Eur J Pharmacol. 1979 Nov 16; 59(3-4):267-76.
Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes.[J Pharmacol Exp Ther. 1980]

Poddar MK, Dewey WL

J Pharmacol Exp Ther. 1980 Jul; 214(1):63-7.
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.[J Neurosci. 2004]

Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM

J Neurosci. 2004 May 5; 24(18):4393-400.
Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area.[J Neurosci. 1988]

Einhorn LC, Johansen PA, White FJ

J Neurosci. 1988 Jan; 8(1):100-12.
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.[Brain Res. 1991]

Herkenham M, Lynn AB, de Costa BR, Richfield EK

Brain Res. 1991 May 3; 547(2):267-74.
Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia.[Neuroscience. 2003]

Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, Garcia-Segura LM

Neuroscience. 2003; 119(1):309-18.
Review Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.[Neuropharmacology. 2005]

Lupica CR, Riegel AC

Neuropharmacology. 2005 Jun; 48(8):1105-16.
Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids.[Eur J Neurosci. 2002]

Szabo B, Siemes S, Wallmichrath I

Eur J Neurosci. 2002 Jun; 15(12):2057-61.
Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study.[Neuroscience. 2000]

Cheer JF, Marsden CA, Kendall DA, Mason R

Neuroscience. 2000; 99(4):661-7.

Classically conditioned responses in opioid and cocaine dependence: a role in relapse?[NIDA Res Monogr. 1988]

Childress AR, McLellan AT, Ehrman R, O'Brien CP

NIDA Res Monogr. 1988; 84():25-43.
Review Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.[Ann N Y Acad Sci. 2001]

Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR

Ann N Y Acad Sci. 2001 Jun; 937():1-26.
Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats.[Eur J Pharmacol. 1992]

Rossetti ZL, Hmaidan Y, Gessa GL

Eur J Pharmacol. 1992 Oct 20; 221(2-3):227-34.
Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration.[Brain Res. 1992]

Weiss F, Markou A, Lorang MT, Koob GF

Brain Res. 1992 Oct 16; 593(2):314-8.
Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats.[J Neurosci. 1996]

Weiss F, Parsons LH, Schulteis G, Hyytiä P, Lorang MT, Bloom FE, Koob GF

J Neurosci. 1996 May 15; 16(10):3474-85.
[Not Available].[Experientia. 1946]

TODD AR

Experientia. 1946 Feb 15; 2():55-60.
Clinical studies of cannabis tolerance and dependence.[Ann N Y Acad Sci. 1976]

Jones RT, Benowitz N, Bachman J

Ann N Y Acad Sci. 1976; 282():221-39.
Marijuana withdrawal among adults seeking treatment for marijuana dependence.[Addiction. 1999]

Budney AJ, Novy PL, Hughes JR

Addiction. 1999 Sep; 94(9):1311-22.
Abstinence symptoms following smoked marijuana in humans.[Psychopharmacology (Berl). 1999]

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW

Psychopharmacology (Berl). 1999 Feb; 141(4):395-404.
Review The cannabis withdrawal syndrome.[Curr Opin Psychiatry. 2006]

Budney AJ, Hughes JR

Curr Opin Psychiatry. 2006 May; 19(3):233-8.
Review Marijuana withdrawal syndrome in the animal model.[J Clin Pharmacol. 2002]

Lichtman AH, Martin BR

J Clin Pharmacol. 2002 Nov; 42(S1):20S-27S.
Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.[J Pharmacol Exp Ther. 1996]

Aceto MD, Scates SM, Lowe JA, Martin BR

J Pharmacol Exp Ther. 1996 Sep; 278(3):1290-5.
Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.[Eur J Pharmacol. 2001]

Aceto MD, Scates SM, Martin BB

Eur J Pharmacol. 2001 Mar 23; 416(1-2):75-81.
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.[Eur J Pharmacol. 1995]

Aceto MD, Scates SM, Lowe JA, Martin BR

Eur J Pharmacol. 1995 Aug 25; 282(1-3):R1-2.
Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.[Eur J Pharmacol. 1995]

Tsou K, Patrick SL, Walker JM

Eur J Pharmacol. 1995 Jul 14; 280(3):R13-5.
Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal.[Eur J Neurosci. 1999]

Diana M, Muntoni AL, Pistis M, Melis M, Gessa GL

Eur J Neurosci. 1999 Mar; 11(3):1037-41.
Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.[Eur J Pharmacol. 1999]

Tanda G, Loddo P, Di Chiara G

Eur J Pharmacol. 1999 Jul 2; 376(1-2):23-6.

Determination and characterization of a cannabinoid receptor in rat brain.[Mol Pharmacol. 1988]

Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC

Mol Pharmacol. 1988 Nov; 34(5):605-13.
Structure of a cannabinoid receptor and functional expression of the cloned cDNA.[Nature. 1990]

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI

Nature. 1990 Aug 9; 346(6284):561-4.
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.[Science. 1992]

Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R

Science. 1992 Dec 18; 258(5090):1946-9.
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.[Biochem Pharmacol. 1995]

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR

Biochem Pharmacol. 1995 Jun 29; 50(1):83-90.
Review Cannabinoid CB1 receptors control conditioned drug seeking.[Trends Pharmacol Sci. 2005]

De Vries TJ, Schoffelmeer AN

Trends Pharmacol Sci. 2005 Aug; 26(8):420-6.
Review Drug addiction.[Curr Top Behav Neurosci. 2009]

Justinova Z, Panlilio LV, Goldberg SR

Curr Top Behav Neurosci. 2009; 1():309-46.

Review Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.[Neuropharmacology. 2005]

Lupica CR, Riegel AC

Neuropharmacology. 2005 Jun; 48(8):1105-16.
Review Role of endogenous cannabinoids in synaptic signaling.[Physiol Rev. 2003]

Freund TF, Katona I, Piomelli D

Physiol Rev. 2003 Jul; 83(3):1017-66.
Review Endocannabinoid signaling in the brain.[Science. 2002]

Wilson RI, Nicoll RA

Science. 2002 Apr 26; 296(5568):678-82.
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors.[J Neurosci. 2004]

Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL

J Neurosci. 2004 Jan 7; 24(1):53-62.
Review Supply and demand for endocannabinoids.[Trends Neurosci. 2011]

Alger BE, Kim J

Trends Neurosci. 2011 Jun; 34(6):304-15.
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.[Nature. 2001]

Wilson RI, Nicoll RA

Nature. 2001 Mar 29; 410(6828):588-92.
The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission.[Neuron. 2010]

Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, Kita Y, Hashimoto K, Shimizu T, Watanabe M, Sakimura K, Kano M

Neuron. 2010 Feb 11; 65(3):320-7.

Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.[J Neurosci. 2007]

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM

J Neurosci. 2007 Jan 24; 27(4):791-5.
Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events.[J Neurosci. 2008]

Aragona BJ, Cleaveland NA, Stuber GD, Day JJ, Carelli RM, Wightman RM

J Neurosci. 2008 Aug 27; 28(35):8821-31.
Review Cannabinoid CB1 receptors control conditioned drug seeking.[Trends Pharmacol Sci. 2005]

De Vries TJ, Schoffelmeer AN

Trends Pharmacol Sci. 2005 Aug; 26(8):420-6.
Review The endocannabinoid system in brain reward processes.[Br J Pharmacol. 2008]

Solinas M, Goldberg SR, Piomelli D

Br J Pharmacol. 2008 May; 154(2):369-83.
Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens.[J Neurochem. 2003]

Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C

J Neurochem. 2003 Feb; 84(4):698-704.
Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.[Psychopharmacology (Berl). 2005]

Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL, Pistis M

Psychopharmacology (Berl). 2005 Dec; 183(3):368-77.

Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens.[J Neurochem. 2003]

Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C

J Neurochem. 2003 Feb; 84(4):698-704.
Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.[Psychopharmacology (Berl). 2005]

Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL, Pistis M

Psychopharmacology (Berl). 2005 Dec; 183(3):368-77.
Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.[J Neurosci. 2007]

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM

J Neurosci. 2007 Jan 24; 27(4):791-5.

Review Cue reactivity and cue reactivity interventions in drug dependence.[NIDA Res Monogr. 1993]

Childress AR, Hole AV, Ehrman RN, Robbins SJ, McLellan AT, O'Brien CP

NIDA Res Monogr. 1993; 137():73-95.
Review Dissecting motivational circuitry to understand substance abuse.[Neuropharmacology. 2009]

Wheeler RA, Carelli RM

Neuropharmacology. 2009; 56 Suppl 1():149-59.
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.[Neuroreport. 2004]

Le Foll B, Goldberg SR

Neuroreport. 2004 Sep 15; 15(13):2139-43.
Review Cannabinoid CB1 receptors control conditioned drug seeking.[Trends Pharmacol Sci. 2005]

De Vries TJ, Schoffelmeer AN

Trends Pharmacol Sci. 2005 Aug; 26(8):420-6.
Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.[Neuropsychopharmacology. 2008]

Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR

Neuropsychopharmacology. 2008 Nov; 33(12):2870-7.
Review Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure.[Psychopharmacology (Berl). 2006]

Epstein DH, Preston KL, Stewart J, Shaham Y

Psychopharmacology (Berl). 2006 Nov; 189(1):1-16.
Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.[Neuron. 2012]

Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, Loriaux AL, Schetters D, Pattij T, Roitman MF, Lichtman AH, Cheer JF

Neuron. 2012 Jan 26; 73(2):360-73.

The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.[Neuropharmacology. 2008]

Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR

Neuropharmacology. 2008 Jan; 54(1):129-40.
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade.[Psychopharmacology (Berl). 2009]

Forget B, Coen KM, Le Foll B

Psychopharmacology (Berl). 2009 Sep; 205(4):613-24.
The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake.[Br J Pharmacol. 2011]

Gamaleddin I, Guranda M, Goldberg SR, Le Foll B

Br J Pharmacol. 2011 Nov; 164(6):1652-60.
Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.[Neuron. 2012]

Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, Loriaux AL, Schetters D, Pattij T, Roitman MF, Lichtman AH, Cheer JF

Neuron. 2012 Jan 26; 73(2):360-73.
Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels.[Cell Mol Life Sci. 2006]

van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V

Cell Mol Life Sci. 2006 Jun; 63(12):1410-24.
Review Cellular signal transduction by anandamide and 2-arachidonoylglycerol.[Chem Phys Lipids. 2000]

Howlett AC, Mukhopadhyay S

Chem Phys Lipids. 2000 Nov; 108(1-2):53-70.
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors.[J Neurosci. 2004]

Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL

J Neurosci. 2004 Jan 7; 24(1):53-62.
The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission.[Neuron. 2010]

Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, Kita Y, Hashimoto K, Shimizu T, Watanabe M, Sakimura K, Kano M

Neuron. 2010 Feb 11; 65(3):320-7.

Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.[Neuron. 2012]

Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, Loriaux AL, Schetters D, Pattij T, Roitman MF, Lichtman AH, Cheer JF

Neuron. 2012 Jan 26; 73(2):360-73.

Save items

Similar articles in PubMed

Cited by other articles in PMC

Links

Recent Activity